110 related articles for article (PubMed ID: 28033686)
1. EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrations.
Schotten N; Laarakkers CM; Roelofs RW; Origa R; van Kraaij MG; Swinkels DW
Am J Hematol; 2017 Mar; 92(3):E29-E31. PubMed ID: 28033686
[No Abstract] [Full Text] [Related]
2. Immunoassay for human serum erythroferrone.
Ganz T; Jung G; Naeim A; Ginzburg Y; Pakbaz Z; Walter PB; Kautz L; Nemeth E
Blood; 2017 Sep; 130(10):1243-1246. PubMed ID: 28739636
[TBL] [Abstract][Full Text] [Related]
3. Erythroferrone, the new iron regulator: evaluation of its levels in Egyptian patients with beta thalassemia.
El-Gamal RAE; Abdel-Messih IY; Habashy DM; Zaiema SEG; Pessar SA
Ann Hematol; 2020 Jan; 99(1):31-39. PubMed ID: 31834456
[TBL] [Abstract][Full Text] [Related]
4. Marathon Run-induced Changes in the Erythropoietin-Erythroferrone-Hepcidin Axis are Iron Dependent.
Tomczyk M; Kortas J; Flis D; Kaczorowska-Hac B; Grzybkowska A; Borkowska A; Lewicka E; Dabrowska-Kugacka A; Antosiewicz J
Int J Environ Res Public Health; 2020 Apr; 17(8):. PubMed ID: 32316587
[TBL] [Abstract][Full Text] [Related]
5. Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone.
Ciniselli CM; De Bortoli M; Taverna E; Varinelli L; Pizzamiglio S; Veneroni S; Bonini C; Orlandi R; Verderio P; Bongarzone I
Expert Rev Proteomics; 2015; 12(6):695-701. PubMed ID: 26496240
[TBL] [Abstract][Full Text] [Related]
6. Is the erythropoietin-erythroferrone-hepcidin axis intact in human neonates?
Bahr TM; Ward DM; Jia X; Ohls RK; German KR; Christensen RD
Blood Cells Mol Dis; 2021 May; 88():102536. PubMed ID: 33450539
[TBL] [Abstract][Full Text] [Related]
7. Erythropoiesis and Iron Parameters in Transfusion-dependent and Nontransfusion-dependent Thalassemias.
Ozturk Z; Gumuslu S; Yalcin K; Kupesiz A
J Pediatr Hematol Oncol; 2021 Jul; 43(5):186-192. PubMed ID: 34157011
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Erythroferrone, Hepcidin, and Iron Overload Status in Iraqi Transfusion-Dependent β-Thalassemia Major Patients.
Smesam HNK; Albuthabhak HAQ; Arjmand S; Al-Hakeim HK; R Siadat SO
Hemoglobin; 2020 Jul; 44(4):272-277. PubMed ID: 32718192
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis and Iron Homeostasis in Non-Transfusion-Dependent Thalassemia Patients with Extramedullary Hematopoiesis.
Huang Y; Liu R; Wei X; Liu J; Pan L; Yang G; Lai Y
Biomed Res Int; 2019; 2019():4504302. PubMed ID: 30834265
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion.
Cavallaro F; Duca L; Pisani LF; Rigolini R; Spina L; Tontini GE; Munizio N; Costa E; Cappellini MD; Vecchi M; Pastorelli L
Can J Gastroenterol Hepatol; 2017; 2017():6843976. PubMed ID: 28191453
[No Abstract] [Full Text] [Related]
11. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.
Huang Y; Lei Y; Liu R; Liu J; Yang G; Xiang Z; Liang Y; Lai Y
Int J Med Sci; 2019; 16(2):302-310. PubMed ID: 30745811
[No Abstract] [Full Text] [Related]
12. Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferrone.
Diepeveen L; Roelofs R; Grebenchtchikov N; van Swelm R; Kautz L; Swinkels D
PLoS One; 2021; 16(7):e0254851. PubMed ID: 34283879
[TBL] [Abstract][Full Text] [Related]
13. Serum erythropoietin levels in patients with beta thalassemia major and intermedia.
Nişli G; Kavakli K; Aydinok Y; Oztop S; Cetingül N
Pediatr Hematol Oncol; 1997; 14(2):161-7. PubMed ID: 9089744
[TBL] [Abstract][Full Text] [Related]
14. Serum Hepcidin as a Diagnostic Marker of Severe Iron Overload in Beta-thalassemia Major.
Kaddah AM; Abdel-Salam A; Farhan MS; Ragab R
Indian J Pediatr; 2017 Oct; 84(10):745-750. PubMed ID: 28600663
[TBL] [Abstract][Full Text] [Related]
15. Hepcidin-25/erythroferrone ratio predicts improvement of anaemia in haemodialysis patients treated with ferric citrate hydrate.
Hara M; Nakamura Y; Suzuki H; Asao R; Nakamura M; Nishida K; Kenmotsu S; Inagaki M; Tsuji M; Kiuchi Y; Ohsawa I; Goto Y; Gotoh H
Nephrology (Carlton); 2019 Aug; 24(8):819-826. PubMed ID: 30239062
[TBL] [Abstract][Full Text] [Related]
16. Analytical and biological assessment of circulating human erythroferrone.
Appleby S; Chew-Harris J; Troughton RW; Richards AM; Pemberton CJ
Clin Biochem; 2020 May; 79():41-47. PubMed ID: 32032568
[TBL] [Abstract][Full Text] [Related]
17. Hepcidin as a potential biomarker for blood doping.
Leuenberger N; Bulla E; Salamin O; Nicoli R; Robinson N; Baume N; Saugy M
Drug Test Anal; 2017 Jul; 9(7):1093-1097. PubMed ID: 27758046
[TBL] [Abstract][Full Text] [Related]
18. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
[TBL] [Abstract][Full Text] [Related]
19. Serum erythropoietin levels in thalassemia major and intermedia.
Chaisiripoomkere W; Jootar S; Chanjarunee S; Ungkanont A
Southeast Asian J Trop Med Public Health; 1999 Dec; 30(4):786-8. PubMed ID: 10928378
[TBL] [Abstract][Full Text] [Related]
20. Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia.
Origa R; Cazzola M; Mereu E; Danjou F; Barella S; Giagu N; Galanello R; Swinkels DW
Haematologica; 2015 May; 100(5):e169-71. PubMed ID: 25596269
[No Abstract] [Full Text] [Related]
[Next] [New Search]
